Status:
COMPLETED
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
Lead Sponsor:
Instituto Mexicano del Seguro Social
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-65 years
Brief Summary
Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
Detailed Description
Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma whose are treated with cytoreductive therapy and stem cell transplant.
Eligibility Criteria
Inclusion
- Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage III ( Durie-Salmon) No severe comorbidities -
Exclusion
- Pregnancy HIV + Refuse treatment
- \-
Key Trial Info
Start Date :
June 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT01234129
Start Date
June 1 2002
End Date
December 1 2009
Last Update
November 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tertiary reference oncology center
Mexico City, Mexico City, Mexico, 06725